August 1, 2007 -- Sinovac Biotech Ltd. (AMEX:SVA), a China-based maker of vaccines, signed an exclusive agreement with the China division of GlaxoSmithKline (GSK) to promote and market Anflu, a seasonal flu vaccine, developed by Sinovac. Anflu has not been a big seller for Sinovac in the past. GSK China will market the drug to adults, while Sinovac will distribute the vaccine to children. Sinovac said the company would pursue similar partnerships as a way to increase revenues. More details...
